Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Discuss both options with the clinical team if you're eligible
The Phase 2 trial enrolled participants with obesity and evaluated multiple dose levels over 48 weeks: 1 mg dose: 8.7% average body weight reduction 4 mg dose (escalated from 2 mg): 17.1% average body weight reduction 8 mg dose (escalated from 2 mg): 22.8% average body weight reduction 12 mg dose (escalated from 2 mg): 24.2% average body weight reduction Placebo: 2.1% average body weight reduction Those Phase 2 numbers were striking enough
Atul Malothra presented findings from the Surmount OSA trial, focusing on the potential of tirzepatide in treating obesity-related Obstructive Sleep Apnea (OSA)
Kubota N, Yano W, Kubota T, Yamauchi T, Itoh S, Kumagai H, et al
Think of it as a clear, practical roadmap to help you achieve your goals
Given these roles, vitamin B6 deficiency can severely impact both the central and peripheral nervous systems (6)
